secwatch.observer — SEC 8-K summary
======================================

Issuer:     Travere Therapeutics, Inc. (TVTX)
CIK:        0001438533
Form:       8-K
Filed at:   2025-05-16T23:59:59+00:00
Accession:  0001438533-25-000034
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Travere stockholders approve 4M-share increase in 2018 equity plan at annual meeting
--------------------------------------------------------------------------------

- Stockholders approved amendment to 2018 Equity Incentive Plan, increasing authorized shares by 4,000,000 (71,802,001 votes for).
- Ten directors elected to serve until 2026 annual meeting; all received majority votes with broker non-votes of ~4.4M.
- Advisory vote on named executive officer compensation passed with 71,929,269 votes for.
- Ratification of Ernst & Young as independent auditor for FY2025 approved (79,001,421 votes for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000034/0001438533-25-000034-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1438533/000143853325000034/tvtx-20250515.htm
  HTML page:      https://secwatch.observer/filing/0001438533-25-000034

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer